366 Efficacy of mycotoxin deactivators on health and growth of newly weaned pigs under chronic dietary challenges of deoxynivalenol
Abstract The efficacy of mycotoxin deactivators on health and growth performance of newly weaned pigs (27 d-old) fed diets naturally contaminated with deoxynivalenol was investigated. Sixty pigs were housed individually and assigned to 5 treatments for 34 d subdivided into 3 phases: NC (no added deoxynivalenol); PC (deoxynivalenol at 2 mg/kg); CYC (PC + clay/yeast culture based product, 0.2%); CYE (PC + clay/yeast cell wall/plant extracts/antioxidants based product, 0.2%); and CYB (PC + clay/inactivated yeast/botanicals/antioxidants based product, 0.2%). Blood was taken at d 14 and 34. Intestinal mucosa was taken at d 34. Data were analyzed using Proc Mixed of SAS with pre-planned contrasts. Deoxynivalenol reduced (P < 0.05) ADG in P3. Pigs fed CYC had greater (P < 0.05) ADG during overall period, ADFI during P3, and gain/feed during P2 than PC. At d 14, deoxynivalenol reduced (P < 0.05) BUN/creatinine and tended to reduce (P = 0.088) BUN. Pigs fed CYB tended to have greater (P = 0.059) AST than PC. At d 34, pigs fed CYC (P = 0.083) and CYB (P = 0.068) tended to have lower serum CPK than PC. Pigs fed CYE had lower (P < 0.05) BUN/creatinine than PC. Deoxynivalenol tended to increase (P = 0.068) malondialdehydes and decrease (P = 0.072) glutathione in jejunal mucosa. Pigs fed CYE and CYB had lower (P < 0.05) malondialdehydes, whereas pigs fed CYB had greater (P < 0.05) glutathione and tended to have lower (P = 0.079) jejunal IgA than PC. Pigs fed CYC (P = 0.066) and CYE (P = 0.099) tended to have lower jejunal IL8 than PC. In conclusion, deoxynivalenol compromised growth performance and intestinal health. The mycotoxin deactivators could enhance intestinal health of pigs fed diets with deoxynivalenol without affecting liver function.